- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02925325
Music Therapy for Major Depressive Disorder Residual Symptoms (MTMDDRS)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
GENERAL PURPOSE:
To evaluate the clinical changes related to the application of music therapy as a treatment for Residual Symptoms of Depression.
SPECIFIC OBJECTIVES:
- Compare the pre and post treatment of residual symptoms by the HAM-D-21, BDI, SCL-90-R and CIDRS levels.
- Compare the change of pre and post treatment obtained by the instruments for quality of life (WHOQOL-BREF), functioning (GAF and PSP) and perceived stress (PSS) values.
METHOD
Design - A randomized controlled trial with two treatment arms: the experimental group Music Therapy (MT); and control group Usual (TU) treatment. MT treatment group will design and will be completed in a period of two months, with an outline of 8 sessions (one per week). The TU corresponds to the usual clinical psychiatric treatment (drug) assigned by the attending physician in the INPRF.
POPULATION - patients attending the outpatient department of the National Institute of Psychiatry "Ramon de la Fuente" between 20 and 45, considered in remission of major depressive disorder (MDD) (DSM-IV) score ≤7 be included points on the Hamilton Depression Scale of (HAM-D-21) and / or ≤9 points in the Beck Depression Inventory (BDI), which have had a positive response to drug treatment and / or remain with pharmacotherapy phase continuation or maintenance, and there report or detection of persistent residual symptoms.
In this research, both participants in the control group and the experimental group, remain drug therapy throughout the study according to the instructions of the attending physician, so the period and type of administration shall be the sole decision of the same. In any case this protocol assessments will be conducted as planned. In the case of any change in drug therapy researchers take note of it for consideration in the final results.
SAMPLE SIZE - According to calculations made, the sample size is 48 patients. With an allocation of 24 patients in each treatment (MT and UT). It is considered to recruit an approximate previous historical studies in SRD sample (Fava et al., 1996; Fava et al., 1998).
To calculate the sample size formula for "comparison of two proportions" (Fernández, 2001), which was used as follows:
Where:
n = subjects required in each of the samples
Za = Z value corresponding to the desired risk
Zb = Z value corresponding to the desired risk
p1 = Value of the proportion in the control group, placebo control or usual treatment.
p2 = Value of the proportion in the group of the new treatment, intervention or technique.
p = average of the two proportions p1 and p2
The following data were considered:
- a confidence level of 95% or safety was established.
- A power of 80%.
- the effectiveness of standard treatment in preventing relapse (Fava et al was set at 32%., 1996; Paykel et al., 1999; Fava et al., 1998; Teasdale et al., 2000; Ma & Teasdale, 2004).
- was set at 70% of the desired effectiveness for MT in preventing relapse, considering the performance of psychotherapies reported (Fava et al., 1996; Paykel et al., 1999; Fava et al., 1998; Teasdale et al, 2000; Ma. & Teasdale, 2004).
This accounted for 15% of subjects the possible loss of the sample according to the following formula:
Losses set to n = (1/1-R) shows
n = number of subjects lossless
R = expected loss ratio
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Enrique O Flores Gutierrez, MD PhD
- Phone Number: +525541605381
- Email: florese@imp.edu.mx
Study Locations
-
-
DF
-
Mexico City, DF, Mexico, 14370
- Recruiting
- Instituto Nacional de Psiquiatria Ramon de la Fuente Muñiz
-
Contact:
- Enrique O Flores Gutierrez, MD PhD
- Phone Number: +525541605381
- Email: florese@imp.edu.mx
-
Sub-Investigator:
- Victor A Teran Camarena, BA
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subsequent and file number at the National Institute of Psychiatry "Ramon de la Fuente" patients.
- Male or Female Patients.
- Age 20-45 years.
- Previous diagnosis of MDD according to DSM-IV.
- Presence of residual symptoms, with a score of ≤7 points in the HAM-D-21 and / or ≤9 points in BDI.
- Patients who agree to sign informed consent sheet.
- Patients without a psychotherapeutic treatment during the 8 weeks prior to baseline.
- Patients with any pharmacological antidepressant treatment in continuation phase or maintenance (Eg. SSRIs, benzodiazepines) with good adherence.
Exclusion Criteria:
- Patients with psychotic symptoms.
- Patients with suicidal risk.
- Patients with comorbid Axis I.
- Patients with comorbid Axis II as the primary diagnosis.
- Patients with any type of hearing chronic medical illness, neurological or (Eg. Hearing loss, tinnitus, etc.)
- Patients with addiction to any substance (except caffeine and nicotine).
- Patients with medical or psychological problems related to music (Eg. Amusia or musicogenic Epilepsy.
- Pregnant women.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Music Therapy
Music therapy 8 weekly sessions
|
Music therapy (MT) treatment focuses on the use of 2 techniques of intervention: receptive MT and active MT.
The work of receptive application is described as the use of prerecorded music or executed by the music therapist with effect on the patient, without the latter's active involvement in the psychotherapeutic process of musical creation.
While the active application, both the music therapist and patient are involved in musical creation, for example, the use of voice, body and musical instruments (Muñoz, 2008).
Contemplate their psychotherapeutic possibilities in 3 different dimensions of patient: body, emotional and social work, as explained above.
Treatment with MT, as in cognitive behavioral therapy, includes breathing exercises, stress-relaxation techniques, psychoeducation, and exercises for the management of irrational thoughts and erratic behavior patterns (Dobson and Dozois, 2010).
|
ACTIVE_COMPARATOR: Usual Treatment
It is the usual medical treatment.
|
It is the usual medical treatment that patients with major depressive disorder in remission but with residual symptom receives at the sponsor institution in a monthly basis.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Hamilton Depression Rating Scale
Time Frame: 3 times: Baseline, Change from Baseline at the end of 2 Months Music Therapy and change from baseline at 3 months follow up
|
3 times: Baseline, Change from Baseline at the end of 2 Months Music Therapy and change from baseline at 3 months follow up
|
Clinical Interview for Depression and Related Syndromes
Time Frame: 3 times: Baseline, Change from Baseline at the end of 2 Months Music Therapy and change from baseline at 3 months follow up
|
3 times: Baseline, Change from Baseline at the end of 2 Months Music Therapy and change from baseline at 3 months follow up
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Symptom Checklist 90 Revised (SCL-90-R)
Time Frame: 3 times: Baseline, Change from Baseline at the end of 2 Months Music Therapy and change from baseline at 3 months follow up
|
3 times: Baseline, Change from Baseline at the end of 2 Months Music Therapy and change from baseline at 3 months follow up
|
Beck Depression Inventory
Time Frame: 3 times: Baseline, Change from Baseline at the end of 2 Months Music Therapy and change from baseline at 3 months follow up
|
3 times: Baseline, Change from Baseline at the end of 2 Months Music Therapy and change from baseline at 3 months follow up
|
WHO Quality of Life-BREF (WHOQOL-BREF)
Time Frame: 3 times: Baseline, Change from Baseline at the end of 2 Months Music Therapy and change from baseline at 3 months follow up
|
3 times: Baseline, Change from Baseline at the end of 2 Months Music Therapy and change from baseline at 3 months follow up
|
Personal and social performance scale (PSP)
Time Frame: 3 times: Baseline, Change from Baseline at the end of 2 Months Music Therapy and change from baseline at 3 months follow up
|
3 times: Baseline, Change from Baseline at the end of 2 Months Music Therapy and change from baseline at 3 months follow up
|
Perceived stress scale (PSS)
Time Frame: 3 times: Baseline, Change from Baseline at the end of 2 Months Music Therapy and change from baseline at 3 months follow up
|
3 times: Baseline, Change from Baseline at the end of 2 Months Music Therapy and change from baseline at 3 months follow up
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Global of Functioning Assessment Scale (GAF)
Time Frame: 3 times: Baseline, Change from Baseline at the end of 2 Months Music Therapy and change from baseline at 3 months follow up
|
3 times: Baseline, Change from Baseline at the end of 2 Months Music Therapy and change from baseline at 3 months follow up
|
Collaborators and Investigators
Investigators
- Study Chair: Enrique O Flores Gutierrez, MD PhD, Instituto Nacional de Psiquiatría Dr. Ramón de la Fuente
- Principal Investigator: Jorge Julio González Olvera, MD PHD, Instituto Nacional de Psiquiatría Dr. Ramón de la Fuente
Study record dates
Study Major Dates
Study Start
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- INPRF_MUS_THER_MDD
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Major Depressive Disorder
-
Shalvata Mental Health CenterUnknownMAjor Depressive DisorderIsrael
-
York UniversityCentre for Addiction and Mental HealthSuspendedDisorder, Major DepressiveCanada
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDDIndia
-
Gangnam Severance HospitalCompletedMajor Depressive Disorder(MDD)Korea, Republic of
-
University College, LondonCompletedUnipolar Major Depressive DisorderUnited Kingdom
-
Fundació Institut de Recerca de l'Hospital de la...Fondo de Investigacion SanitariaUnknown
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDD)India
-
Repurposed Therapeutics, Inc.Unknown
-
GlaxoSmithKlineCompletedMajor Depressive Disorder (MDD)United States
-
AccexibleRecruitingMajor Depressive Disorder (MDD)Spain
Clinical Trials on Music therapy
-
Case Comprehensive Cancer CenterCompletedMultiple Myeloma | Hodgkin Lymphoma | Non-Hodgkin LymphomaUnited States
-
University of North Carolina, Chapel HillNorth Carolina Translational and Clinical Sciences InstituteCompletedAutonomic Nervous System Imbalance | Hypothalamic Pituitary Adrenal Axis SuppressionUnited States
-
Wayne State UniversityCompletedNeurological DisordersUnited States
-
Icahn School of Medicine at Mount SinaiCompletedSARS-CoV 2 | Dyspnea | Post Covid-19 RespiratoryUnited States
-
Icahn School of Medicine at Mount SinaiCompleted
-
Children's Healthcare of AtlantaCompletedRespiratory Syncytial Virus InfectionsUnited States
-
University of MilanUnknownCritical Illness | Music Therapy | Hypnotics and SedativesItaly
-
Beth Israel Medical CenterCompleted
-
Inge Nygaard PedersenAalborg UniversityUnknown
-
Yale UniversityCompletedPatient Satisfaction | Intravitreal Injections | Patient AnxietyUnited States